The role of polypeptide growth factors in human carcinomas: New targets for a novel pharmacological approach

Pharmacological Reviews

Volumn 52, Issue 2, 2000, Pages 179-206

  Favoni, Roberto E ^a   De Cupis, Alessandra ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLYPEPTIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA; DRUG EFFECT; DRUG SCREENING; HUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; GROWTH SUBSTANCES; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PEPTIDES; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0034084453     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (363)

1. Aboud-Pirak E, Hurwitz E, Pira ME, Bellot F, Schlessinger J and Sela M (1988) Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80:1605-1611.
2. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorack HF and Brown LF (1996) Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptor in ovarian borderline and malignant neoplasms. Lab Invest 74:1105-1115.
3. Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hamalainen E, Hasegawa T and Okada H (1991) Urinary excretion of lignans and isoflavonid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 54:1093-1100.
4. Agrawal SA (1992) Antisense oligonucleotides as antiviral agents. Trends Biotechnol 10:152-158.
5. Akagi Y, Liu W, Zebrowski B, Xie K and Eliis LM (1998) Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58:4008-4014.
6. Amaya E, Musci TJ and Kirschener MW (1991) Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in Xenopus embryos. Cell 66:257-270.
7. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Khan MA, Jones RT and Harris HH (1998) Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer 78:233-239.
8. Anthony LB, Winn DH, Johnson KR, Hande KR and Oates JA (1994) Chronic high-dose octreotide in neuroendocrine neoplasm. Ann Oncol 5:139.
9. Antoniades HN and Owen AJ (1988) Growth factor and regulation of cell growth. Annu Rev Med 33:445-463.
10. Ariad S, Seymour L and Bezwoda WR (1991) Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of progression. Breast Cancer Res Treat 20:11-17.
11. Arrick BA, Korc M and Derynck R (1990) Differential regulation of expression of three transforming growth factor β species in human breast cancer cell lines by estradiol. Cancer Res 50:299-303.
12. Arteaga CL, Dugger TC and Hurd SD (1996) The multifunctional role of transforming growth factor (TGF)-βs on mammary epithelial cell biology. Breast Cancer Res Treat 38:49-56.
13. Barni S, Lissoni P, Brivio F, Fumagalli M, Melini D, Cataldo M, Rovelli F and Tancini G (1994) Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin. Tumori 80:212-215.
14. Barrett-Lee P, Travers M, Luqmani Y and Coombers RC (1990) Transcripts for transforming growth factors in human breast cancer: Clinical correlation. Br J Cancer 81:612-617.
15. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr and Mendelsohn J (1993) Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327-1333.
16. Basilico C and Moscatelli D (1992) The FGF family of growth factors and oncogenes. Adv Cancer Res 59:115-165.
17. Beitner-Johnson D, Blakesley VA, Shen-Orr Z, Jimenez M, Stannard B, Wang LM, Pierce J and LeRoith D (1996) The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS. Modulation by insulin growth factor-1 (IGF-1) and enhanced IGF-1 signaling. J Biol Chem 271:9287-9290.
18. Bellusci S, Moens G, Gaudino G, Comoglio P, Nakamura T, Thiery JP and Jouanneau J (1994) Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 9:1091-1099.
19. waf1/cip1 and transforming growth factor β1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res 4:1499-1506.
20. Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ and McKenna WG (1996) The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res 56:1727-1730.
21. Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM and Muschel RJ (1998) Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 58:1754-1761.
22. Berthois Y, Dong XF and Martin PM (1989) Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7. Biochem Biophys Res Commun 159:126-131.
23. Bhatavdekar JM, Patel DD, Karelia NH, Vora HH, Ghosh N, Shah NG, Balar DB and Trivedi SN (1994) Tumor markers in patients with advanced breast cancer as prognosticators: A preliminary study. Breast Cancer Res Treat 30:293-297.
24. Biasoli G, Botta M, Ciomei M, Corelli F, Grandi M, Manetti F, Mongelli N and Paio A (1993) New heterocyclic analogues of suramin with bFGF inhibiting activity. Synthesis, SAR and possible mode of action. Med Chem Res 4:202-210.
25. Bilder GE, Krawiec JA, McVety K, Gazit A, Gilon C, Lyall R, Zilberstein A, Levitzki A, Perrrone MH and Schreiber AB(1991) Tryphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am J Physiol 260:C721-C730.
26. Bishop WR, Petrin J, Wang L, Ramesh U and Doll RJ (1990) Inhibition of protein kinase C by the tyrosine kinase inhibitor erbstatin. Biochem Pharmacol 40:2129-2135.
27. Blood CH and Zetter BR (1990) Tumor interactions with the vasculature: Angiogenesia and tumor metastasis. Biochem Biophys Acta 1032:89-118.
28. Bogden AE, Taylor JE, Moreavi JP, Coy DH and LePage DJ (1990) Response of human lung tumor xenografts to treatment with a somatostatin analog (somatuline). Cancer Res 50:4360-4365.
29. Bondy CA, Werner AH, Roberts CT Jr and LeRoith D (1990) Cellular pattern of insulin-like growth factor-1 (IGF1) and type-1 IGF receptor gene expression in early organogenesis: Comparison with IGF2 gene expression. Mol Endocrinol 4:1386-1398.
30. Boocock CA, Charnock-Jones S, Sharkey AM, McLaren J, Baker PJ, Wright KA, Twentyman PR and Smith SK (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87:506-516.
31. Boschelli DH, Wu Z, Klutchko SR, Showalter HD, Hamby JM, Lu GH, Major TC, Dahring TK, Batley B, Panek RL, Keiser J, Hartl BG, Kraker AJ, Klosh WD, Roberts BJ, Patmore S, Elliott WL, Steinkampf R, Bradford LA, Hallak H and Doherty AM (1998) Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: Identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. J Med Chem 41:4365-4377.
32. Bowen-Pope DF, Malpass TW, Foster DM and Ross R (1984) Platelet-derived growth factor in vivo: Levels, activity, and rate of clearance. Blood 64:458-469.
33. Brattain MG, Ko Y, Banerji SS, Wu G and Willson JKV (1996) Defects of TGF-β receptor signaling in mammary cell tumorigenesis. J Mammary Gland Biol Neoplasia 1:365-372.
34. Brattstrom D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Brodin O and Wagenius G (1998) Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anti-cancer Res 18:1123-1128.
35. Bronzert DA, Pantazis P, Antoniades HN, Kasid A, Davidson N, Dickson RB and Lippman ME (1987) Synthesis and secretion of platelet derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci USA 84:5763-5767.
36. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorack HF, Senger DR, Connolly JL and Schintt SJ (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86-91.
37. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorack HF and Senger DR (1993) Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143:1255-1262.
38. Burgering BMT and Coffer PJ (1995) Protein kinase B (c-Akt) in phosphatidylinositol-3OH kinase signal transduction. Nature (Lond) 376:599-602.
39. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A and Comoglio P (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629-642.
40. Carpenter CL and Cantley LC (1996) Phosphoinositide kinase. Curr Opin Cell Biol 8:153-158.
41. Carpenter G and Cohen S (1990) Epidermal growth factor. J Biol Chem 265:7709-7712.
42. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J and Letarte MC (1992) Endegolin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 267:19027-19030.
43. Chen RH and Derynck R (1994) Homomeric interactions between type II transforming growth factor-β receptors. J Biol Chem 259:22868-22874.
44. Chen T, Carter D, Garrigue-Antar L and Reiss M (1998) Transforming growth factor-β type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res 58:4805-4810.
45. Chevalley T, Strong DD, Mohan S, Baylink DJ and Linkhart TA (1996) Evidence for a role of insulin-like growth factor binding proteins in glucocorticoid inhibition of normal human osteoblast-like cell proliferation. Eur J Endocrinol 134:591-601.
46. Chin YE, Kitagawa M, Su WC, You Z, Iwamoto Y and Fu X (1996) Cell growth arrest inhibition of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1. Science (Wash DC) 272:719-722.
47. Ciomei M, Pastori W, Mariani M, Sola F, Grandi M and Mongelli N (1994) New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem Pharmacol 47:295-302.
48. Clark JW, Santos-Moore A, Stevenson LE and Frackelton AR Jr (1996) Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway. Int J Cancer 65:186-191.
49. Clemmons DR, Camacho-Hubner C, Coronado E and Osborne CK (1990) Insulin-like growth factor binding protein secretion by breast cancer cell lines: Correlation with estrogen receptor status. Endocrinology 127:2679-2686.
50. Cohen S (1986) Nobel lecture. Epidermal growth factor. Biosci Rep 6:1017-1028.
51. Crews JR, Maier LA, Yu YH, Hester S, O'Briant K, Leslie DS, DeSombre K, George K, George SL, Boyer CM, Argon Y and Bast RC Jr (1992) A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast cancer cell lines. Int J Cancer 51:772-779.
52. Crickard K, Gross JL, Crickard M, Yoonessi M, Lele S, Herblin WF and Eidsvoog K (1994) Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol 55:277-284.
53. Cross DAE, Alessi DR, Cohen P, Andjelkovich L and Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (Lond) 378:785-789.
54. Cross M and Dexter MT (1991) Growth factors in development, transformation and tumorigenesis. Cell 64:271-280.
55. Dabrow MB, Francesco MR, McBrearty FX and Caradonna S (1998) The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 71:29-37.
56. Dameron KM, Volpert OV, Tainsky MA and Bouck N ( 1994) Control of angiogenesis: In fibroblasts by p53 regulation of thrombospondin-1. Science (Wash DC) 265: 1582-1584.
57. Damstrup L, Voldborg BR, Spang-Thomsen M, Brunner N and Skovgaard Poulsen H (1998) In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer 78:631-640.
58. Datto MB, Yu Y and Wang XF (1995) Functional analysis of the transforming growth factor-β responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem 270: 28623-28628.
59. c-erbB-2-ricin. A chain. (RTA) immunotoxin therapy alone and in combination with anti-P170EGFR-RTA in ovarian cancer cells. Clin Cancer Res 4:2545-2550.
60. de Cupis A, Ciomei M, Pirani P, Ferrera A, Ardizzoni A and Favoni RE (1997) Anti-insulin-like growth factor-I activity of a novel polysulphonated distamycin A derivative in human lung cancer. Br J Pharmacol 120:537-543.
61. de Cupis A and Favoni RE (1997) Oestrogen and growth factor cross-talk in breast carcinoma: A specific target for novel antioestrogen. Trends Pharmacol Sci 18: 245-251.
62. de Cupis A, Noonan D, Pirani P, Ferrera A, Clerico L and Favoni RE (1995) Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-1-induced proliferation of human breast cancer-derived cells. Br J Pharmacol 116:2391-2400.
63. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C, Baum M, Walton P, Sutcliffe F and Wakeling AE (1994) Investigation of a new pure antioestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54:408-411.
64. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS and Berger WH (1987) Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor by human tumors. Cancer Res 47:707-712.
65. De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D and Press O (1992) Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 52:1916-1923.
66. Di Blasio AM, Cremonesi L, Vigano P, Ferrari M, Gospodarowicz D, Vignali M and Jaffe RB (1993) Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms. Am J Obstet Gynecol 169:1517-1523.
67. Dionne CA, Jaye M and Schlessinger J (1991) Structural diversity and binding of FGF receptors. Ann NY Acad Sci 638:161-166.
68. Doerr ME and Jones JI (1996) The roles of integrines and extracellular matrix proteins in the insulin-like growth factor-I stimulated chemotaxis of human breast cancer cells. J Biol Chem 271:2443-2447.
69. Du W, Lebowitz PF and Prendergast GF (1999) Cell growth inhibition by farnesyl-transferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 19:1831-1840.
70. Dudek H, Datta SR, Franke TF, Bimbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR and Greenberg ME (1997) Regulation of neuronal survival by the serine-treonine protein kinase AKT. Science (Wash DC) 275:661-665.
71. Dunn SE, Ehrlich M, Sharp NJH, Reiss K, Solomon G, Hawkins R, Baserga R and Barrett JC (1998) A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 58:3353-3361.
72. Eccles SA, Modjtahedi H, Box G, Court W, Sandle J and Dean CJ (1995) Significance of the c-erb family receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. Invasion Metastasis 14:337-348.
73. Eguchi J, Nomata K, Kanda S, Igawa T, Taide M, Koga S, Matsuya F, Kanetake H and Saito Y (1992) Gene expression and immunohistochemical localization of basic fibroblast growth factor in renal cell carcinoma. Biochem Biophys Res Comm 183:937-944.
74. Eisenberger MA and Reyno LM (1994) Suramin. Cancer Treat Rev 20:259-273.
75. Ellerbroek SM, Hudson LG and Stack MS (1998) Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer 78:331-337.
76. Fantl WJ, Johnson DE and Williams LT (1993) Signalling by receptor tyrosine kinases. Annu Rev Biochem 62:453-481.
77. Favoni RE, de Cupis A, Bruno S, Yee D, Ferrera A, Pirani P, Costa A and Decensi A (1998) Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Br J Cancer 77:2138-2147.
78. Favoni RE, de Cupis A, Ravera F, Cantoni C, Pirani P, Ardizzoni A, Noonan D and Biassoni R (1994a) Expression and function of the insulin-like growth factor-I system in human non-small cell lung cancer and normal lung cell lines. Int J Cancer 56:858-866.
79. Favoni RE, Ravera F, Pirani P, Ardizzoni A, Noonan D and de Cupis A (1994b) Suramin interferes with auto/paracrine insulin-like growth factor I-controlled loop on human lung cancer cell lines. Eur J Pharmacol 264:199-206.
80. Ferrara N and Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851-859.
81. Fidler IL and Nicolson GL (1987) The process of cancer invasion and metastasis. Cancer Bull 39:126-131.
82. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6.
83. Folkman J and Klagsbrun M (1987) Angiogenic factors. Science (Wash DC) 235:442-447.
84. Folkman J, Watson K, Ingber D and Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (Lond) 339:58-61.
85. Fontana JA, Nervi C, Shao ZM and Jetten AM (1992) Retinoid antagonism of estrogen-responsive transforming growth factor alpha and pS2 expression in breast carcinoma cells. Cancer Res 52:3938-3945.
86. Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G (1997) Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3:861-865.
87. Forsythe JA, Jang BH, Iyer NV, Agani F, Leung SW, Koos RD and Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613.
88. Franke TF, Kaplan DR and Cantley LC (1997) PI3K: Downstream AKTion blocks apoptosis. Cell 88:435-437.
89. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR and Tsichlis PN (1995) The protein kinase encoded by the AKT proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:727-736.
90. Freiss G, Prébois C, Rochefort H and Vignon F (1990) Anti-steroidal and anti-growth factor activities of anti-estrogens. J Steroid Biochem Mol Biol 37:777-781.
91. Freiss G, Puech C and Vignon F (1998) Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells. Mol Endocrinol 12:568-579.
92. Freiss G and Vignon F (1994) Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Mol Endocrinol 8:1389-1396.
93. Fritz G, Kaina B and Aktories K (1995) The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J Biol Chem 270:25172-25177.
94. Gallagher JT, Lyon M and Steward WP (1986) Structure and function of heparin sulfate proteoglycans. Biochem J 236:313-325.
95. Garcia AM, Rowell C, Ackerman K, Kowalczk JJ and Lewis MD (1993) Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J Biol Chem 268:18415-18418.
96. Garrett MD and Workman P (1999) Discovering novel chemotherapeutic drugs for third millennium. Eur J Cancer 35:2010-2030.
97. Gebauer G, Jager W and Lang N (1998) mRNA expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues and metastatic breast cancer cells. Anticancer Res 18:1191-1196.
98. Gibbs JB and Oliff A (1997) The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37:143-166.
99. Giguere V (1994) Retinoic acid receptors and cellular retinoid binding proteins: Complex interplay in retinoid signaling. Endocr Rev 15:61-79.
100. Ginsburg E and Vonderhaar BK (1991) Stimulation of growth of human breast cancer cells (T47D) by Platelet Derived Growth Factor. Cancer Lett 58:137-144.
101. Gold LI (1999) The role for transforming growth factor-β (TGF-β) in human cancer. Crit Rev Oncol 10:303-360.
102. Gottardis MM, Lamph WW, Shalinsky DR, Wellstein A and Heyman RA (1996) the efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat 38:85-96.
103. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P and Rosen EM (1993) Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 90:1937-1941.
104. Gucev ZS, Kelley KM, Rosenfeld RG and Oh Y (1996) Insulin-like growth factor binding protein-3 (IGF-BP3) mediates retinoic acid (RA)- and transforming growth factor-β2 (TGF-β2)-induced growth inhibition in human breast cancer cells. Cancer Res 56:1545-1550.
105. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF and Brown LF (1995) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87:1237-1245.
106. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D and Lassar AB (1995) Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Wash DC) 267:1018-1021.
107. Han RNN, Mawdsley C, Souza P, Tanswell AK and Post M (1992) Platelet-derived growth factors and growth-related genes in rat lung: Immunolocalization during fetal development. Pediatr Res 31:323-329.
108. Hanauske AR, Osborne CK, Chamness GC, Clark GM, Forseth BJ, Buchok JB, Arteaga CL and Von Hoff DD (1987) Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. Eur J Cancer Clin Oncol 23:545-551.
109. Harris AL, Nicholson S and Sainsbury R (1992) Epidermal growth factor receptor and other oncogenes as prognostic markers. J Natl Cancer Inst 11:181-187.
110. Heldin CH (1995) Dimerization of cell surface receptors in signal transduction. Cell 80:213-223.
111. Heldin CH (1996) Protein tyrosine kinase receptors. Cancer Surv 27:7-24.
112. Henis YI, Moustakas A, Lin HY and Lodish HF (1994) The type II and III transforming growth factor-β receptors form oligomers. J Cell Biol 126:139-154.
113. Hiscox S and Jiang WG (1999) Hepatocyte growth factor/scatter factor disrupts epithelial tumour cell-cell adhesion: Involvement of β-catenin. Anticancer Res 19:509.
114. Houck KA, Ferrara N, Winer J, Cachinanes G, Li B and Leung DW (1991) The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814.
115. Houck LA, Leung DW, Rowland AM, Winer J and Ferrara N (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037.
116. Howell A, DeFriend D, Robertson J, Blamey R and Walton P (1995) Response to a specific antioestrogen (ICI182780) in tamoxifen-resistant breast cancer. Lancet 345:29-30.
117. Hunter T (1995) Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signalling. Cell 80:225-236.
118. Huynh HT, Tetenes E, Wallace L and Pollak M (1993) In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res 53:1727-1730.
119. Huynh HT, Yang X and Pollak M (1996) Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271:1016-1021.
120. Igawa T, Kanda S, Kanetake H, Saitoh Y, Ichihara A, Tomita Y and Nakamura T (1991) Hepatocyte growth factor is a potent mitogen for cultured rabbit renal tubular epithelial cells. Biochem Biophys Res Commun 174:831-838.
121. Ikeda E, Achen MG, Breier G and Risau W (1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 34:19761-19768.
122. Jahner D and Hunter T (1991) The ras-related gene rhoB is an immediate early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts. Mol Cell Biol 11:3682-3690.
123. James GL, Brown MS and Cobb MH (1994) Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells. J Biol Chem 269:27705-27714.
124. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD and Marsters JC Jr (1993) Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells. Science (Wash DC) 260:1937-1942.
125. Jaques G, Rotsch M, Wegmann C, Worsch U, Maasberg M and Havemann K (1988) Production of immunoreactive insulin-like growth factor I and response to exogenous IGF-I in small cell lung cancer cell lines. Exp Cell Res 176:336-343.
126. Jaye M, Lyall RM, Mudd R, Schlessinger J and Sarver N (1988) Expression of acidic fibroblast growth factor cDNA confers growth advantage and tumorigenesis to Swiss 3T3 cells. EMBO J 7:963-969.
127. Jhappan C, Geiser AG, Kordon EC, Bagheri D, Hennighausen AB, Roberts AB, Smith GH and Merlino M (1993) Targeting expression of a transforming growth factor-β1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J 12:1835-1845.
128. Jin L, Fusch A, Schnitt SJ, Yao Y, Joseph A, Lamszus K, Park M, Goldberg ID and Rosen EM (1997) Expression of scatter and c-met receptor in benign and malignant breast tissue. Cancer 79:749-760.
129. Johnson DE, Lu H, Chen H, Werner S and Williams LT (1991) The human fibroblast growth factor receptor genes: A common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol 11:4627-4634.
130. Johnson DE and Williams LT (1993) Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60:1-41.
131. Jones JL and Clemmons DR (1995) Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34.
132. Kaiser U, Schardt C, Brandscheidt D, Wollmer E and Havemann K (1993) Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer. J Cancer Res Clin Oncol 119:665-668.
133. Kan M, Zhang G, Zarnegar R, Michalopoulos G, Myochen Y, McKeehan WL and Stevens JL (1991) Hepatocyte growth factor/hepatopoietin A stimulates the growth of rat kidney proximal tubule epithelial cells (RPTE), rat nonparenchymal liver cells, human melanoma cells, mouse keratinocytes and stimulates anchorage independent growth of SV-40 transformed RPTE. Biochem Biophys Res Commun 174:331-337.
134. Karnes WE Jr, Weller SG, Adjei PN, Kottke TJ, Glenn KS, Gores GJ and Kaufmann SH (1998) Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology 114:930-939.
135. Kastrinakis WV, Ramchurren N, Rieger KM, Hess DT, Loda M, Steele G and Summerhayes IC (1995) Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 11:647-652.
136. Katzenellenbogen BS and Norman J (1990) Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: Interrelationships among insulin, insulin-like growth factor-I, serum and estrogen. Endocrinology 126:891-898.
137. Kawai T, Hiroi S and Torikata C (1997) Expression in lung carcinomas of platelet-derived growth factor and its receptor. Lab Invest 77:431-436.
138. Kawamoto K, Onodera H, Kondo S, Kan S, Ikeuchi D, Maetani S and Imamura M (1998) Expression of insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: Correlation with tumor progression, proliferative activity and survival. Oncology 55:242-248.
139. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson D and Rosenfeld RG (1995) Insulin-like growth factor-binding proteins (IGF-BPs) and their regulatory dynamics. Int J Biochem Cell Biol 28:619-637.
140. Kevil CH, De Benedetti A, Payne DK, Coe LL, Laurox FS and Alexander JS (1996) Translocation regulation of vascular permeability factor by eukariotic initiation factor 4E: Implications for tumor angiogenesis. Int J Cancer 65:785-790.
141. Kiefer P, Jaques G, Schoneberger J, Heinrich G and Havemann K (1991) Insulin-like growth factor binding proteins expression in human small cell lung cancer cell lines. Exp Cell Res 192:414-417.
142. Kieser A, Weich HA, Brandner G, Marme D and Kolch W (1994) p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9:963-969.
143. Kiess W, Haskell JF, Lee L, Greenstein LA, Miller BE, Aarson AL, Rechler MM and Nissley SP (1987) An antibody that blocks insulin-like growth factor (IGF) binding to the type II receptor is neither an agonist nor an inhibitor of IGF-stimulated biological responses in L6 myoblasts. J Biol Chem 262:12745-12751.
144. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Kato M and Lee C (1996) Genetic changes in transforming growth factor beta (TGF-beta) receptor type 1 gene correlates with insensitivity to TCP-beta 1 in human prostate cancer. Cancer Res 56:44-48.
145. Kimura G, Kasuya J, Giannini S, Honda Y, Mohan S, Kawachi M, Akimoto M and Fujita-Yamaguchi Y (1996) Insulin-like growth factor (IGF) system components in human prostatic cancer cell lines: LNCaP, DU145, and PC-3 cells. Int J Urol 3:39-46.
146. Kita Y, Tseng J, Horan T, Wen J, Philo J, Chan D, Ratzkin B, Pacifici R, Brankow D, Hu S, Luo Y, Wen D, Arakawa T and Nicolson M (1996) ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-HER-2 monoclonal antibodies. Biochem Biophys Res Commun 226:59-69.
147. Klagsburn M and Baird A (1991) A dual receptor system is required for basic fibroblast growth factor activity. Cell 67:229-231.
148. Klijn JGM, Berns PMJJ, Schmitz PIM and Foekens JA (1992) The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev 13:3-17.
149. Klohs WD, Fry DW and Kraker AJ (1997) Inhibitors of tyrosine kinase. Curr Opin Oncol 9:562-568.
150. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A and Gibbs JB (1993) Selective inhibition of ras-dependent transformation by a famesyltransferase inhibitor. Science (Wash DC) 260: 1934-1937.
151. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez, Graham SL and Hamilton K (1995) Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1:792-797.
152. Koli KM and Arteaga CL (1996) Complex role of tumor cell transforming growth factor (TGF)-βs on breast carcinoma progression. J Mammary Gland Biol Neoplasm 1:365-372,
153. Koli K and Keski-Oja J (1995) 1,25 dihydroxyvitamin D3 enhances the expression of transforming growth factor β1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 55:1540-1546.
154. Kopreski MS, Lipton A, Harvey HA and Kumar R (1996) Growth inhibition of breast cancer cell lines by combinations of anti-p185HER2 monoclonal antibody and cytokines. Anticancer Res 16:433-436.
155. Krusekopf S, Chauchereau A, Milgrom E, Henderson D and Cato AC (1991) Cooperation of postgestational steroids with epidermal growth factor in activation of gene expression in mammary tumor cells. J Steroid Biochem Mol Biol 40:239-245.
156. Kunkel MW, Hook KE, Howard CT, Przybranowski SSS, Roberts BJ, Elliott WL and Leopold WR (1996) Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Investig New Drugs 13:295-302.
157. Lahm H, Amstad P, Wyniger J, Yilmaz A, Fischer JR, Schreyer M and Givel JC (1994) Blockade of the insulin-like growth factor-I receptor inhibits growth of human colorectal cancer cells: Evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer 58:452-459.
158. Lambert S, Collette J, Gillis J, Franchimont P, Desaive C and Gol-Winkler R (1991) Tumor IGF-II content in a patient with a colon adenocarcinoma correlates with abnormal expression of the gene. Int J Cancer 48:826-830.
159. Lambert S, Vivario J, Boniver J and Gol-Winkler R (1990) Abnormal expression and structural modification of the insulin-like growth-factor-II gene in human colorectal cancer. Int J Cancer 46:405-410.
160. Lamonerie T, Lavialle C, Haddada H and Brison O (1995)IGF-2 autocrine stimulation in tumorigenic clones of a human colon-carcinoma cell line. Int J Cancer 61:587-592.
161. Langdon SP and Smyth JF (1995) Inhibition of cell signalling pathways. Cancer Treatment Rev 21:65-89.
162. Larcher F, Robles AI, Duran H, Murillas R, Quintanilla M, Cano A, Conti CJ and Jorcano JL (1996) Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with
163. Lawrence DS and Diu J (1998) Protein kinase inhibitors: The tyrosine-specific protein kinases. Pharmacol Ther 77:81-114.
164. Lebowitz PF, Casey PJ, Predergast GC and Thissen JA (1997a) Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 272:15591-15594.
165. Lebowitz PF, David JP and Piendergast GC (1995) Evidence that farnesyl transferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 15:6613-6622.
166. Lebowitz PF and Prendergast GC (1995) Non-Ras targets for famesyltransferase inhibitors: Focus on Rho. Oncogene 17:1439-1447.
167. Lebowitz PF, Sakamuro D and Predergast GC (1997b) Farnesyltransferase inhibitors induce apoptosis in Ras-transformed cells denied substratum attachment. Cancer Res 57:708-713.
168. Lee AV, Hilsenbeck SG and Yee D (1998) IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat 47:295-302.
169. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J and Day NE (1991) Dietary effects on breast cancer risk in Singapore. Lancet 337:1197-1200.
170. Leitzel K, Teramoto K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L and Lipton A (1995) Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135.
171. Lemmon MA and Schlessinger J (1994) Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 19:459-463.
172. Leonard DM (1997) Ras farnesyltransferase: A new therapeutic target. J Med Chem 40:2971-2990.
173. Leventhal PS and Feldman EL (1997) Insulin-like growth factors as growth regulators of cell motility: Signaling mechanism. Trends Endocrinol Metab 8:1-6.
174. Levi-Montalcini R (1987) The nerve growth factor 35 years later. Science (Wash DC) 237:1154-1162.
175. Levitski A and Gazit A (1995) Tyrosine kinase inhibition: An approach to drug development. Science (Wash DC) 267:1782-1788.
176. Levitski A and Gilon C (1991) Tryphostins as molecular tools and potential antiproliferative drugs. Trends Pharmacol Sci 12:171-174.
177. Levy AO, Levy NS and Goldberg MA (1996) Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 271:2746-2753.
178. Levy AO, Levy NS, Wegner S, and Goldberg MA (1995) Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270: 13333-13340.
179. Li C, Wang J, Wilson PB, Kumar P, Levine E, Hunter RD and Kumar S (1998) Role of transforming growth factor β3 in lymphatic metastasis in breast cancer. Int J Cancer 79:455-459.
180. Lippman ME, Dickson RB, Gelmann EP, Rosen N, Knabbe C, Bates S, Bronzert D, Huff K and Kasid A (1987) Growth regulation of human breast cancer occurs through regulated growth factor secretion. J Cell Biochem 35:1-16.
181. Lopez-Casillas F, Payne HM, Andres JL and Massagué J (1994) Betaglycan can act as a dual modulator of TGFβ access to signaling receptors: Mapping of ligand binding and GAG attachment sites. J Cell Biol 124:557-568.
182. Lopez-Lopez R, Peters GJ, van Leonen AC, Pizao PE, van Rijswijk REN, Wagstaff J and Pinedo HM (1992) The effect of schedule, protein binding and growth factors on the activity of suramin. Int J Cancer 51:921-926.
183. Ludwig T, LeBorgne R and Hoflack B (1995) Roles for mannose 6-phosphate receptors in lysosomal enzyme sorting, IGF-II binding and clathrin-coat assembly. Trends Cell Biol 5:202-206.
184. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D and Tang C (1996) The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 38:57-66.
185. Ma L, Gauville C, Berthois Y, Degeorges A, Millot G, Martin PM and Calvo F (1998) Role of epidermal-growth-factor receptor in tumor progression in transformed human mammary epithelial cells. Int J Cancer 78:112-119.
186. MacDonald A and Habib FK (1992) Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 67:177-182,
187. Maculay VM (1992) Insulin-like growth factors and cancer. Br J Cancer 65:311-320.
188. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T and Sowa M (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77:858-863.
189. Marcelli M, Haidacher SJ, Plymate SR and Birnbaum RS (1995) Altered growth factor and insulin-like growth factor-binding protein-3 production in PC-3 prostatic carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology 136:1040-1048.
190. Massagué J, Attisano L and Wrana JL (1994) The TGF-β family and its composite receptors. Trends Cell Biol 4:172-178.
191. Mathieu M, Rochefort H, Bareton B, Prebois C and Vignon F (1990) Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. Mol Endocrinol 4:1327-1335.
192. Matsumoto K and Nakamura T (1992) Hepatocyte growth factor: Molecular structure, roles in liver regeneration and other biological function. Crit Rev Oncol 3:27-54.
193. Matsumoto K, Tajima H and Nakamura T (1991) Hepatocyte growth factor is a potent stimulator of human melanocyte DNA synthesis and growth. Biochem Biophys Res Commun 176:46-51.
194. Mattern J, Koogami R and Volm M (1995) Vascular endothelial growth factor expression and angiogenesis in nonsmall cell lung carcinomas. Int J Oncol 6:1059-1062.
195. Mattern J, Koogami R and Volm M (1996) Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma. Br J Cancer 73:931-934.
196. Mazue NM, Chen EY, Yeh P, Laderoute KR and Giaccia AJ (1996) Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 56:3436-3440.
197. McMahon G, Sun L and Liang C (1998) Protein kinase inhibitors: Structural determinants for target specificity. Curr Opin Drug Discov Dev 1:131-146.
198. Mesiano S, Ferrara N and Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer. Am J Pathol 153:1249-1256.
199. Miller DA, Pelton RW, Derynck J and Moses HL (1990) Transforming growth factor-β: A family of growth regulatory peptides. Ann NY Acad Sci 593:208-217.
200. Minniti CP, Kohn EC, Grubb JH, Sly WS, Oh Y, Muller HL, Rosenfeld RG and Helman LJ (1992a) The insulin-like growth factor-II (IGF-II) mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells. J Biol Chem 267:9000-9004.
201. Minniti CP, Maggi M and Helman LJ (1992b) Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res 52:1830-1835.
202. Mise M, Arii S, Higashituju H, Furutani M, Nuwano M, Harada T, Ishigami SI, Toda Y, Nakayama H, Fujumoto M, Fujita J and Imamura M (1996) Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23:455-464.
203. Modiano JF, Kokai Y, Weiner DB, Pykett MJ, Nowell PC and Lyttle CR (1991) Progesterone augments proliferation induced by epidermal growth factor in a feline mammary adenocarcinoma cell line. J Cell Biochem 45:196-206.
204. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, Farrus B, Latre ML, Escriche C, Estape J and Ballesta A (1998) c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: Prognostic value. Breast Cancer Res Treat 51:109-119.
205. Montesano R, Matsumoto K, Nakamura T and Orci L (1991) Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67:901-908.
206. Mukhopadhyay D, Tsiokas L and Sukhamata VP (1995) Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55:6161-6165.
207. Murphy LC, Murphy LJ, Dubik D, Bell GI and Shiu RP (1988) Epidermal growth factor gene expression in human breast cancer cells: Regulation of expression by progestins. Cancer Res 48:4555-4560.
208. Murphy LJ, Shuterland RL, Stead B, Murphy LC and Lazarus L (1986) Progestin regulation of epidermal growth factor in human mammary carcinoma cells. Cancer Res 46:728-734.
209. Murray PA, Barrett-Lee P, Travers M, Luqmani Y, Powels TJ and Coombes HC (1993) The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 67:1408-1412.
210. Murrill WB, Brown NM, Zhang JX, Manzolillo PA, Barnes S and Lamartiniere CA (1996) Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis 17:1451-1457.
211. Myers M, Sun XJ and White M (1994) The IRS-1 signalling system. Trends Biol Sci 19:289-293.
212. Myoken Y, Myoken Y, Okamoto T, Kan M, Sato JD and Takada K (1994a) Release of fibroblast growth factor-1 by human squamous cell carcinoma correlates with autocrine cell growth. In Vitro Cell Dev Biol Anim 30:790-795.
213. Myoken Y, Myoken Y, Okamoto T, Sato JD and Takada K (1994b) Immunohistochemical localization of fibroblast growth factor-1 (FGF-1) and FGF-2 in oral squamous cell carcinoma (SCC). J Oral Pathol Med 23:451-456.
214. Nakamura T (1991) Structure and function of hepatocyte growth factor. Prog Growth Factor Res 3:67-85.
215. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y and Nakamura T (1997) Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: In vitro analysis of tumor-stromal interactions. Cancer Res 57:3305-3313.
216. Nakamura T, Nawa K and Ishiara A (1984) Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Byophys Res Commun 122:1450-1459.
217. Naldini L, Vigna E, Ferracini R, Longati P, Gandino L, Prat M and Comoglio PM (1991a) The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol Cell Biol 11:1793-1803.
218. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narshimhan RP, Hartman G, Zarnegar H, Michalopoulos GK and Comoglio PM (1991b) Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 10:2867-2878.
219. Nass SJ and Dickson RB (1998) Epidermal growth factor-independent cell cycle progression is altered in mammary epithelial cells that overexpress c-myc. Clin Cancer Res 4:1813-1822.
220. Neckers L, Whitesell L, Rosolen A and Geselowitz DA (1992) Antisense inhibition of oncogene expression. Crit Rev Oncog 3:175-231.
221. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO and Blarney RW (1994) Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy. Breast Cancer Res Treat 29:117-125.
222. Norgaard P, Housgaard S, Poulsen HS and Spang-Thomsen M (1995) Transforming growth factor-β and cancer. Cancer Treat Rev 21:367-403.
223. Normanno N, Bianco C, Damiano V, de Angelis E, Selvman MP, Grassi M, Magliulo G, Tortora G, Bianco AR, Mendelshon J, Salomon DS and Ciardiello F (1996) Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. Clin Cancer Res 2:601-609.
224. Obermair A, Speiser P, Reisenberg K, Ullrich R, Czerwenka K, Kaider A, Zeillenger R, Miksche M (1998) influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Lett 130:69-76.
225. Ogasawara M and Sirbasku DA (1988) A new serum-free method of measuring growth factor activities for human breast cancer cells in culture. In Vitro Cell Dev Biol 24:911-920.
226. Oh Y (1998) IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treat 47:283-293.
227. Oh Y, Muller HL, Ng L and Rosenfeld RG (1995) TGF-β-induced cell growth inhibition in human breast cancer cells is mediated through IGF-BP3 action. J Biol Chem 270:13589-13592.
228. Oh Y, Nagalla SN, Yamanaka Y, Kim H, Wilson L and Rosenfeld RG (1996) Identification and characterization of insulin-like growth factor binding protein (IG-FBP)-7: Recombinant human mac25 protein specifically binds IGF-I and IGF-II. J Biol Chem 271:30322-30325.
229. Olivero M, Rizzo M, Mededdu R, Casadio C, Pennacchietti S, Nicotra MR, Prat M, Maggi G, Arena N, Natali PG, Comoglio PM and Di Renzo MF (1996) Overexpression and activation of hepatocyte growth/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 74:1862-1868.
230. Olson TA, Mohanraj D and Ramakrishnan S (1995) The selective inhibition of vascular permeability factor (vpf) expression in ovarian carcinoma cell lines by gonadotropin releasing hormone (gnrh) agonist. Int J Oncol 6:905-910.
231. Paik S (1992) Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 22:31-38.
232. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF and Ramakrishnan S (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98-106.
233. Pan MG, Florio T and Stork PJS (1992) G protein activation of a hormone-stimulated phosphatase in human tumor cells. Science (Wash DC) 256:1215-1217.
234. Parker MG (1993) Action of "pure" antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 26:131-137.
235. Parrizas M and LeRoith D (1997) Insulin-like growth factor-I inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 138:1355-1358.
236. Pawson T (1995) Protein modules and signalling networks. Nature (Lond) 373:573-580.
237. HER/ neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671.
238. Pekonen F, Partanen S, Maiken T and Rutamen EM (1988) Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48:2343-2347.
239. Pepper MS, Matsumoto K, Nakamura T, Orci L and Montesano R (1992) Hepatocyte growth factor increased urokinase-type plasminogen activator (uPA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J Biol Chem 267:20493-20496.
240. Perry RR, Kang Y and Greaves BR (1995) Relationship between tamoxifen-induced growth factor β1 expression, cytostasis and apoptosis in human breast cancer cells. Br J Cancer 72:1441-1446.
241. Petch LA, Harris J, Raymond VW, Blasband A, Lee DC and Earp HS (1990) A truncated secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue. Mol Cell Biol 10:2973-2982.
242. Peterson G and Barnes S (1993) Genistein and Biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 22:335-345.
243. Peterson G and Barnes S (1996) Genistein inhibits both estrogen and growth factor stimulated proliferation of human breast cancer cells. Cell Growth Differ 7:1345-1351.
244. Philips A, Chalbos D and Rochefort H (1993) Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 268:14103-14108.
245. Pietrzowski Z, Mulholland G, Gomella IL, Jameson BA, Wernicke D and Baserga R (1993) Inhibition of growth prostatic cancer cell lines by peptide analogues of insulin-lute growth factor 1. Cancer Res 5:1102-1106.
246. Pollak M, Huynh H and Levebvre SP (1992) Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 22:91-100.
247. Pollak M and Richard M (1990) Suramin blockade of insulin-like growth factor 1 stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 82:1349-1352.
248. Prat M, Crepaldi T, Gaudino L, Giordano S, Longati P and Comoglio P (1991) C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol Cell Biol 11:5954-5962.
249. Prendergast GC (1999) Targeting farnesyltransferase: Is ras relevant? Proc Am Soc Clin Oncol Annu Meet 18:22-28.
250. Prendergast GC, Davide JP, deSolms SJ, Giuliani EA, Graham SL, Gibbs JB, Oliff A and Kohl NE (1994) Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14:4193-4202.
251. Radulovic S, Comaru-Schally AM, Milovanovic S and Schally AV (1993) Somatostatin analog RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Pancreas 8:88-97.
252. Raines EW, Bowen-Pope EF and Ross R (1984) Plasma binding protein for platelet-derived growth factor that inhibit its binding to cell-surface receptors. Proc Natl Acad Sci USA 81:3424-3428.
253. Rakowicz-Szulczynska EM and Koprowski H (1991) Expression of A-type PDGF receptor in cytoplasm of tumor cell lines synthesising PDGF. Exp Mol Pathol 51:171-178.
254. Rasmussen AA and Cullen KJ (1998) Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res Treat 47:219-233.
255. Ravera F, Miglietta L, Pirani P, Ferrini S and Favoni RE (1993) Suramin-induced growth inhibition and IGF-I binding blockade on human breast carcinoma cell lines: Potentially related events. Eur J Cancer 29:225-230.
256. Rechler MM and Nissley SP (1985) The nature and regulation of the receptors for insulin-like growth factors. Annu Rev Physiol 47:425-442.
257. Reiss M and Barcellos-Hoff MH (1997) The role of transforming growth factor-β in breast cancer: A working hypothesis. Breast Cancer Res Treat 45:81-95.
258. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HJ, Kajstura RJ, Rubin R, Zoltick P and Baserga R (1995) The insulin-like growth factor I receptor protects tumor cell from apoptosis in vivo. Cancer Res 55:2463-2469.
259. Resnik JL, Reichart DB, Huey K, Webster NJG and Seely BL (1998) Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 58:1159-1164.
260. Reynolds K, Farzaneh F, Collins WP, Campbell S, Bourne F, Lawton A, Moghaddam A, Harris AL and Bicknell R (1994) Association of ovarian malignancy with expression of platelet derived endothelial cell growth factor. J Natl Cancer Inst 86:1234-1238.
261. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R and Smith LEH (1996) Oligode-oxynucleotides inhibit retinal neovascularization in a murine model for proliferative retinopathy. Proc Natl Acad Sci USA 93:4851-4856.
262. Rodrigues GA, Naujokas MA and Park M (1991) Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing. Mol Cell Biol 11:2962-2970.
263. Rogler CE, Yang D, Rossetti L, Donohoe J, Alt E, Chang CJ, Rosenfeld R, Neely K and Hintz R (1994) Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 269: 13779-13784.
264. Rosen PP (1983) Tumor emboli in intramammary lymphatics in breast carcinoma: Pathological criteria for diagnosis and clinical significance. Pathol Annu 18:215.
265. Roses DF, Bell DA, Flotte TJ, Taylor R, Ratech H and Dubin N (1982) Pathological predictors of recurrence in Stage I (T1N0M0) breast cancer. Am J Clin Pathol 78:817-820.
266. Ross P, Raines EW and Bowen-Pope DF (1986) The biology of platelet-derived growth factor. Cell 46:155-159.
267. Rotsch M, Maasberg M, Erbil C, Jaques G, Worsch U and Havemann K (1992) Characterization of insulin-like growth factor I receptors and growth effects in human lung cancer cell lines. J Cancer Res Clin Oncol 118:502-508.
268. Rubin R and Baserga R (1995) Biology of disease. Igf-IR. Its role in cell proliferation, apoptosis and tumorigenicity. Lab Invest 73:311-331.
269. Rubin Grandis J, Melhem MF, Barnes EL and Tweardy DJ (1996) Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78:1284-1292.
270. Rubin Grandis J and Tweardy DJ (1993) Elevated levels of transforming growth factor-a and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579-3584.
271. Rubin Grandis J, Tweardy DJ and Melhem MF (1998) Asyncronous modulation of transforming growth factor-a and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 4:13-20.
272. Ruff-Jamison S, Chen K and Cohen S (1995) Epidermal growth factor induces tyrosine phosphorylation and nuclear translocation of STAT5 in mouse liver. Proc Natl Acad Sci USA 92:4215-4218.
273. Russell PJ, Bennett S and Stricker P (1998) Growth factor involvement in progression of prostate cancer. Clin Chem 44:705-723.
274. Sadowski HB, Shuai K, Darnell JE and Gilam MZ (1993) A common nuclear signal transduction pathway activated by growth factor and cytokine receptor. Science (Wash DC) 261:1739-1743.
275. Salomon DS, Brandt R, Ciardiello F and Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev OncolHematol 19:183-232.
276. Sarup JC, Rao KV and Fox CF (1988) Decreased progesterone binding and attenuated progesterone action in cultured human breast carcinoma cells treated with epidermal growth factor. Cancer Res 48:5071-5078.
277. Sasada R, Kurokawa T, Iwana M and Igarashi K (1988) Transformation of mouse BALB/c 3T3 cells with human basic fibroblast growth factor cDNA. Mol Cell Biol 8:588-594.
278. Sathyamoorthy M, Gilsdorf JS and Wang TTY (1998) Differential effect of genistein on transforming growth factor β1 expression in normal and malignant mammary epithelial cells. Anticancer Res 18:2449-2454.
279. Sato K, Terada K, Sugiyama T, Takahashi S, Saito M, Moriama M, Kiunuma H, Suzuki Y, Kato M and Kao T (1994) Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. Tohoku J Exp Med 173: 355-360.
280. Schally AV (1988) Oncological applications of somatostatin analogues. Cancer Res 48:6977-6985.
281. Schardt C, Rotsch M, Erbil C, Goke R, Richter G and Havemann K (1993) Characterization of insulin-like growth factor-II receptors in human small cell lung cancer cell lines. Exp Cell Res 204:22-29.
282. Scher H, Jodrell D and Iversen J (1992) The use of adaptative control with feedback to individualize suramin dosing. Cancer Res 52:64-70.
283. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelshon J and Cordon-Cardo C (1995) Changing pattern of expression of epidermal growth factor receptor and transforming growth factor-α in the progression of prostatic neoplasms. Clin Cancer Res 1:545-550.
284. Scholar EM and Toews ML (1994) Inhibition of invasion of murine mammary carcinomas cells by the tyrosine kinase inhibitor genistein. Cancer Lett 87:159-162.
285. Scott PAE, Smith K, Poulsom R, De Benedetti A, Bicknell R and Harris AL (1998) Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 77:2120-2128.
286. Sebti SM and Hamilton AD (1997) Inhibition of Ras prenylation: A novel approach to cancer chemotherapy. Pharmacol Ther 74:103-114.
287. Sehgal I, Baley PA and Thompson TC (1996) Transforming growth factor beta 1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 56:3359-3365.
288. Senger DR, Galli SJ, Dvorack AM, Peruzzi CA, Harvey VS and Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Wash DC) 219:983-985.
289. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A and Rosen N (1995) A peptidomimetic inhibitor of farnesyl-protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55: 5302-5309.
290. Seslar S, Nakumara T and Byers SW (1993) Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. Cancer Res 53:1233-1238.
291. Seymour L and Bezwoda WR (1994) Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Treat 32:229-233.
292. Seymour L, Dajee D and Bezwoda WR (1993) Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 26:247-252.
293. Sherwood ER, Fong CJ, Lee C and Kozlowski JM (1992) Basic fibroblast growth factor: A potential mediator of stromal growth in the human prostate. Endocrinology 130:2955-2963.
294. Shima DT, Deutsch U and D'Amore PA (1995) Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in RNA stability. FEBS Lett 370:203-208.
295. Slamon DJ, Godolphil W, Jones La, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Ress MF (1989) Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science (Wash DC) 244:707-712.
296. Slovin SF, Livingston PO, Rosen N, Sepp-Lorenzino L, Kelly WK, Mendelsohn J and Scher HI (1996) Targeted therapy for prostate cancer: The Memorial Sloan-Kettering Cancer Center approach. Semin Oncol 23:41-48.
297. Soderdahl G, Betsholtz C, Johansson A, Nilsson K and Bergh J (1988) Differential expression of platelet-derived growth factor and transforming growth factor genes in small- and non-small-cell human lung carcinoma lines. Int J Cancer 41:636-641.
298. Sola F, Farao M, Pesenti E, Marsiglio A, Mongelli N and Grandi M (1995) Antitumor activity of FCE26644, a new growth factor complexing molecule. Cancer Chemother Pharmacol 36:217-222.
299. Sonnenberg K, Meyer D, Weidner KM and Birchmeier C (1993) Scatter factor/ hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123:223-235.
300. Speirs V, Jenkins S and White MC (1993) Growth factor regulation of 17 beta-hydroxysteroid dehydrogenase activity in a human ovarian cell line: Modulation of 17 beta-estradiol. Anticancer Res 13:1399-1403.
301. Sporn MB and Todaro GJ (1980) Autocrine secretion and malignant transformation of cells. W Engl J Med 303:878-880.
302. Stein CA and Cheng YC (1993) Antisense oligonucleotides as therapeutic agents: Is the bullet really magical? Science (Wash DC) 261:1004-1012.
303. Stewart AJ, Johnson MD, May FE and Westley BR (1990) Role of insulin-like growth factors and type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265:21171-21178.
304. Stoker M, Gherardi E, Perrymman M and Gray J (1987) Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature (Lond) 327:239-242.
305. Story MT, Livingston B, Beaton L, Swartz SJ, Jacobs SC, Begun FP and Lawson RK (1989) Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. Prostate 15:355-365.
306. Strange R, Li F, Saurer S, Burkhardt A and Friis RR (1992) Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 115:49-58.
307. Sun J, Qian Y and Hamilton AD (1998) Both farnesyltransferase and geranylgeranyltransferase inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16:1467-1473.
308. Swisshelm K, Ryan K, Tsuchiya K and Sager R (1995) Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced with retinoic acid. Proc Natl Acad Sci USA 92:4472-4476.
309. Symons M (1996) Rho family GTPases: The cytoskeleton and beyond. Trends Biochem Sci 21:178-181.
310. Takahashi Y, Bucana CD, Clearly KR and Ellis LM (1998) p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 79:34-38.
311. Takahashi Y, Kitadai Y, Bucana CD, Clearly KR and Ellis LM (1995) Expression of vascular endothelial growth and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964-3968.
312. Takahashi Y, Trucker SL, Kitadai Y, Koure AN, Bucana CD, Clearly KR and Ellis LM (1996) Vessel counts and VEGF expression as prognostic factors in node-negative colon cancer. Arch Surg 132:541-546.
313. Takeura N, Yashui W, Kyo E, Yoshida K, Kameda T, Kitadai Y, Abe K, Umezawa K and Tahara E (1991) Effects of tyrosine kinase inhibitor, erbstatin, on cell growth and growth factor/receptor gene expression in human gastric carcinoma cells. Int J Cancer 47:938-942.
314. Takigawa N, Segawa Y, Fujimoto N, Hotta K and Eguchi K (1998) Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 18:1251-1254.
315. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y and Tominaga T (1995) Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1:1031-1034.
316. Tapon N and Hall A (1997) Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr Opin Cell Biol 9:86-92.
317. Tecce R, Digiesi G, Savarese A, Trizio D and Natali PG (1993) Characterization of cytotoxic activity of saporin anti-gp185/HER-2 immunotoxins. Int J Cancer 55: 122-127.
318. Tempfer C, Obermair A, Hefler L, Haesuler G, Gitsch G and Kainz C (1998) Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 92:360-363.
319. Toi M, Hoshina T, Takayanagi T and Tomianga T (1994) Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85:1045-1049.
320. Toi M, Taniguchi T, Ueno T, Asano M, Funata N, Sekiguchi K, Iwanari H and Tominaga T (1998) Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res 4:659-664.
321. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamoki N and Nakamura M (1998) Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77:998-1002.
322. Travers MT, Barrett-Lee PJ, Berger U, Luqmani YA, Gazet JC, Powels TJ and Coombes RC (1988) Growth factor expression in normal, benign, and malignant breast tissue. Br Med J 296:1621-1624.
323. Traxler PM (1997) Protein tyrosine kinase inhibitors in cancer treatment. Exp Opin Ther Patents 7:571-588.
324. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT and Thompson TC (1993) Association of transforming growth factor beta 1 with prostate cancer. Hum Pathol 24:4-9.
325. Tuck AB, Park M, Sterns EE, Boag A and Elliot BE (1996) Coexpression of hepatocyte growth factor and receptor (Met) in human breast cancer. Am J Pathol 148:225-232.
326. Ueno H, Gunn M, Dell K, Tseng A Jr and Williams L (1992) A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor. J Biol Chem 267:1470-1476.
327. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Liberman TA and Schlessinger J (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (Lond) 309:418-425.
328. Ullrich A and Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212.
329. Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, Uchida T, Iinuma H, Hamada M and Takeuchi T (1986) Studies on a new epidermal growth factor receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J Antibiot (Tokyo) 39:170-173.
330. Van Aelst L and D'Souza-Schorey C (1997) Rho GTPases and signaling networks. Genes Dev 11:2295-2322.
331. van der Geer P and Pawson T (1995) The PTB domain: A new protein module implicated in signal transduction. Trends Biochem Sci 20:277-280.
332. Vignon F, Bardon S, Chalbos D, Deroq D, Gili PG and Rochefort H (1987) Antiproliferative effect of progestins in human breast cancer cells, in Hormonal Manipulation of Cancer (Klijn JGM, Pandaens R, and Foekens JA eds) pp 47-54, Ravan Press, New York.
333. Voss JWX and Rosenfeld MG (1992) Anterior pituitary development: Short
334. Wade T, Kasid A, Stein C, LaRocca R, Sargent E, Gomelia L, Myers C and Linehan M (1992) Suramin interference with transforming growth factor-β inhibition of human renal cell carcinoma in culture. J Surg Res 53:195-198.
335. Wagner RA (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature (Lond) 372:333-335.
336. Wakeling A (1990) Therapeutic potential of pure antioestrogens in the treatment of breast cancer. J Steroid Biochem Mol Biol 80:37:771-775.
337. Wang Q, Maloof P, Wang H, Fenig E, Stein D, Nichols G, Denny TN, Yahalom J and Wieder R (1998) Basic fibroblast growth factor downregulates bcl-2 and promotes apoptosis in MCP-7 human breast cancer cells. Exp Cell Res 238:177-187.
338. Wang TTY, Sathyamoorthy N and Phang JM (1996) Molecular effects of genistein on estrogen receptor mediated pathway. Carcinogenesis 17:271-275.
339. sis of simian sarcoma virus. Nature (Lond) 304:35-39.
340. Webster LT Jr (1985) Chemotherapy of parasitic disease, in The Pharmacological Basis of Therapeutics (Gilman AG et al., eds) p 1063, MacMillan, New York.
341. Webster NJG, Rensnik JL, Reichart DB, Strauss B, Haas M and Seely BL (1996) Repression of the insulin receptor promoter by the tumor suppressor gene product p53: A possible mechanism for receptor overexpression in breast cancer. Cancer Res 56:2781-2788.
342. Weckbecker G, Liu R, Tolcsvai L and Bruns C (1992) Antiproliferative effects of the somatostatin analog octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 52:4973-4978.
343. Weckbecker G, Raulf F, Stolz B and Bruns C (1993) Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 60:245-264.
344. Weidner KM, Araki N, Hartmann G, Vandekerkhove J, Weingart S, Rieder H, Fontasch C, Tsubouchi H, Hishida T, Daikuhara Y and Birchmeier W (1991) Evidence for identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA 88:7001-7005.
345. Weidner KM, Beherns J, Vandekerkhove J and Birchmeier W (1990) Scatter factor: Molecular characteristic and effect on the invasiveness of epithelial cells. J Cell Biol 111:2097-2108.
346. Werner H, Karnieli E, Rauscher FJ and LeRoith D (1996) Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93:8318-8323.
347. Witters L, Kumar R, Mahitosh M, Bennett CF, Miraglia L and Lipton A (1999) Antisense oligonucleotides to the epidermal growth factor receptor. Breast Cancer Res Treat 53:41-50.
348. Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP and Curiel DT (1997) An intracellular anti-erb-B-2 single chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther 4:317-322.
349. Wu CW, Chi CW, Su TL, Liu TY, Lui WY and P'eng FK (1998) Serum hepatocyte growth factor level associates with gastric cancer progression. Anticancer Res 18:3657-3660.
350. Xie W, Su K, Wang D, Paterson AJ and Kudlow J (1997) MDA468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21WAF1. Anticancer Res 17:2627-2634.
351. Yaish P, Gazit A, Gilon C and Levitzki A (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science (Wash DC) 242:933-935.
352. Yamashita H, ten Dijeke P, Franzén P, Miyazono K and Heldin CH (1994a) Formation of hetero-oligomeric complexes of type 1 and type II receptors for transforming growth factor-β. J Biol Chem 269:20172-20178.
353. Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, SaijshoJi T and Shin S (1994b) Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54:1630-1633.
354. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S and Hayes DF (1997) Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the Her-2/ c-neu protein. J Clin Oncol 15:2518-2525.
355. Yarden Y and Ullrich A (1988) Growth factor receptor tyrosine kinases. Ann Rev Biochem 57:443-478.
356. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME and Rosen N (1989) Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509-517.
357. Yee D, Sharma J and Hilsenbeck SG (1994) Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst 86:1785-1789.
358. Yoshiji H, Gomez DE, Shibuya M and Thorgeirsson UP (1996) Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56:2013-2016.
359. Zabrecky JR, Lam T, McKenzie SJ and Carney W (1991) The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266:1716-1720.
360. Zalcman G, Closson V, Linares-Cruz G, Lerebours F, Honore N, Tavitian A and Olofsson B (1995) Regulation of Ras-related RhoB protein expression during the cell cycle. Oncogene 10:1935-1945.
361. Zhang L, Kharbanda S, Hanfelt J and Kern FG (1998) Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells. Cancer Res 58:352-361.
362. Zugmaier G, Lippman ME and Wellstein A (1992) Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst 84:1716-1724.
363. Zwick E, Hackel PO, Prenzel N and Ullrich A (1989) The EGF-receptor as a central transducer of heterologous signalling system. Trends Pharmacol Sci 20:408-412.